BioSpace News Archive

Oncolytics Biotech® Inc. reported interim results from the phase 1/2 GOBLET study’s first-line advanced/metastatic pancreatic ductal adenocarcinoma cohort in an abstract published as part of the Society for Immunotherapy of Cancer 37th Annual Meeting.

DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, announced that the company’s management will participate in the BioFuture Conference being held on November 7-9, 2022 at the Lotte New York Palace in New York City, NY.

Ferring Pharmaceuticals today announced the publication in the journal Drugs of its pivotal Phase 3 PUNCH™ CD3 clinical trial data, in which a single dose of RBX2660 demonstrated superiority to placebo as a treatment to reduce recurrence of Clostridioides difficile infection (CDI) after standard-of-care antibiotic treatment in a Bayesian analysis model.

Apros Therapeutics, Inc. announced that they will present interim pharmacokinetic and pharmacodynamic Phase 1 clinical data for APR003 at the 2022 Society for Immunotherapy of Cancer Annual Meeting to be held November 8-12th in Boston, MA.

Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces its business update and its financial position for the quarter ending September 30, 2022.

Nykode Therapeutics ASA announced that its Chief Executive Officer, Michael Engsig, and Chief Business Officer & Co-founder, Agnete Fredriksen, will present and host 1x1 meetings at two upcoming investor conferences in November.

Calliditas Therapeutics AB announced that it will host a Key Opinion Leader Fireside Chat on the IgA Nephropathy treatment landscape in the US on Tuesday, November 8th, 2022 at 1:30pm Eastern Time.

Cerveau Technologies, Inc. announced a license agreement with LEXEO Therapeutics, Inc., which will enable LEXEO to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography scans to assess the status and progression of neurofibrillary tangles in the brain.

BrainStorm Cell Therapeutics Inc. announced the presentation of a poster with new analyses from NurOwn’s placebo-controlled Phase 3 amyotrophic lateral sclerosis trial that account for limitations in the Revised ALS Functional Rating Scale and provide evidence of a clinically meaningful treatment effect.

KalVista Pharmaceuticals, Inc. announced it will participate in a fireside chat at the following investor conferences: Stifel 2022 Healthcare Conference on Tuesday, November 15, 2022 at 1:50 p.m. EST Jefferies London Healthcare Conference on Thursday, November 17, 2022 at 8:35 a.m. GMT